IART
Income statement / Annual
Last year (2023), Integra LifeSciences Holdings Corporation's total revenue was $1.54 B,
a decrease of 1.03% from the previous year.
In 2023, Integra LifeSciences Holdings Corporation's net income was $67.74 M.
See Integra LifeSciences Holdings Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.54 B
|
$1.56 B
|
$1.54 B
|
$1.37 B
|
$1.52 B
|
$1.47 B
|
$1.19 B
|
$992.08 M
|
$882.73 M
|
$928.31 M
|
| Cost of Revenue |
$653.18 M |
$587.36 M |
$597.81 M |
$520.83 M |
$564.68 M |
$571.50 M |
$435.51 M |
$349.09 M |
$326.54 M |
$352.80 M |
| Gross Profit |
$888.39 M |
$970.31 M |
$944.64 M |
$851.03 M |
$952.88 M |
$900.95 M |
$752.73 M |
$642.99 M |
$556.19 M |
$575.50 M |
| Gross Profit Ratio |
0.58 |
0.62 |
0.61 |
0.62 |
0.63 |
0.61 |
0.63 |
0.65 |
0.63 |
0.62 |
| Research and Development
Expenses |
$62.69 M
|
$101.19 M
|
$93.05 M
|
$77.38 M
|
$79.57 M
|
$78.04 M
|
$63.46 M
|
$58.16 M
|
$50.90 M
|
$51.60 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$690.75 M
|
$624.10 M
|
$455.63 M
|
$415.76 M
|
$445.97 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$611.60 M
|
$616.32 M
|
$637.45 M
|
$594.53 M
|
$687.60 M
|
$690.75 M
|
$624.10 M
|
$455.63 M
|
$415.76 M
|
$445.97 M
|
| Other Expenses |
-$40.03 M |
$13.88 M |
$16.91 M |
$27.76 M |
$27.03 M |
$8.29 M |
$1.35 M |
$845,000.00 |
$4.59 M |
-$763,000.00 |
| Operating Expenses |
$714.32 M |
$731.39 M |
$747.41 M |
$699.66 M |
$794.20 M |
$789.95 M |
$707.92 M |
$527.65 M |
$476.61 M |
$509.96 M |
| Cost And Expenses |
$1.37 B |
$1.32 B |
$1.35 B |
$1.22 B |
$1.36 B |
$1.36 B |
$1.14 B |
$876.74 M |
$803.15 M |
$862.76 M |
| Interest Income |
$9.36 M |
$11.92 M |
$6.74 M |
$9.30 M |
$10.78 M |
$2.80 M |
$255,000.00 |
$24,000.00 |
$13,000.00 |
$168,000.00 |
| Interest Expense |
$71.83 M |
$49.59 M |
$50.40 M |
$71.58 M |
$53.96 M |
$64.68 M |
$35.02 M |
$25.80 M |
$23.52 M |
$21.97 M |
| Depreciation &
Amortization |
$123.51 M
|
$121.12 M
|
$123.67 M
|
$118.99 M
|
$114.70 M
|
$115.70 M
|
$88.90 M
|
$72.67 M
|
$9.95 M
|
$12.40 M
|
| EBITDA |
$297.59 M
|
$276.73 M
|
$240.19 M
|
$192.86 M
|
$206.01 M
|
$143.25 M
|
$66.77 M
|
$130.07 M
|
$94.14 M
|
$77.35 M
|
| EBITDA Ratio |
0.19 |
0.18 |
0.16 |
0.14 |
0.14 |
0.1 |
0.06 |
0.13 |
0.11 |
0.08 |
| Operating Income Ratio
|
0.11
|
0.15
|
0.13
|
0.11
|
0.12
|
0.08
|
0.04
|
0.12
|
0.09
|
0.07
|
| Total Other
Income/Expenses Net |
-$93.01 M
|
-$25.03 M
|
$17.45 M
|
-$57.85 M
|
-$118.87 M
|
$8.29 M
|
$1.35 M
|
$845,000.00
|
$4.59 M
|
-$763,000.00
|
| Income Before Tax |
$81.07 M |
$213.89 M |
$214.68 M |
$93.52 M |
$60.10 M |
$57.40 M |
$11.39 M |
$90.41 M |
$60.67 M |
$42.98 M |
| Income Before Tax Ratio
|
0.05
|
0.14
|
0.14
|
0.07
|
0.04
|
0.04
|
0.01
|
0.09
|
0.07
|
0.05
|
| Income Tax Expense |
$13.33 M |
$33.34 M |
$45.60 M |
-$40.37 M |
$9.90 M |
-$3.40 M |
-$53.36 M |
$15.84 M |
$53.82 M |
$8.98 M |
| Net Income |
$67.74 M |
$180.55 M |
$169.08 M |
$133.89 M |
$50.20 M |
$60.80 M |
$64.74 M |
$74.56 M |
-$3.52 M |
$34.00 M |
| Net Income Ratio |
0.04 |
0.12 |
0.11 |
0.1 |
0.03 |
0.04 |
0.05 |
0.08 |
-0 |
0.04 |
| EPS |
0.85 |
2.18 |
2 |
1.58 |
0.59 |
0.73 |
0.83 |
1 |
-0.0476 |
0.52 |
| EPS Diluted |
0.84 |
2.16 |
1.98 |
1.57 |
0.58 |
0.72 |
0.82 |
0.94 |
-0.0476 |
0.52 |
| Weighted Average Shares
Out |
$80.09 M
|
$83.00 M
|
$84.70 M
|
$84.65 M
|
$85.64 M
|
$82.86 M
|
$78.39 M
|
$74.72 M
|
$73.88 M
|
$65.48 M
|
| Weighted Average Shares
Out Diluted |
$80.34 M
|
$83.52 M
|
$85.49 M
|
$85.23 M
|
$86.49 M
|
$84.45 M
|
$79.12 M
|
$79.19 M
|
$73.88 M
|
$65.92 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
